1. Home
  2. LAZ vs SUPN Comparison

LAZ vs SUPN Comparison

Compare LAZ & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lazard Inc.

LAZ

Lazard Inc.

HOLD

Current Price

$47.92

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$51.38

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAZ
SUPN
Founded
1848
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.0B
IPO Year
2004
2010

Fundamental Metrics

Financial Performance
Metric
LAZ
SUPN
Price
$47.92
$51.38
Analyst Decision
Hold
Strong Buy
Analyst Count
8
5
Target Price
$52.75
$61.60
AVG Volume (30 Days)
1.3M
601.1K
Earning Date
05-01-2026
05-05-2026
Dividend Yield
4.21%
N/A
EPS Growth
N/A
N/A
EPS
0.91
N/A
Revenue
$3,186,466,000.00
$392,755,000.00
Revenue This Year
$13.36
$22.70
Revenue Next Year
$13.72
$19.14
P/E Ratio
$50.71
N/A
Revenue Growth
1.48
N/A
52 Week Low
$38.67
$31.16
52 Week High
$58.75
$59.68

Technical Indicators

Market Signals
Indicator
LAZ
SUPN
Relative Strength Index (RSI) 55.27 57.17
Support Level $47.66 $47.85
Resistance Level $51.83 $52.26
Average True Range (ATR) 2.09 2.09
MACD -0.18 0.34
Stochastic Oscillator 69.92 77.34

Price Performance

Historical Comparison
LAZ
SUPN

About LAZ Lazard Inc.

Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: